ArticleAnnals of hematology2026
Pomalidomide re-exposure after drug-related severe hypothyroidism: a case report.
Article in Annals of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pomalidomide, an analogue of lenalidomide and thalidomide, has shown significant activity in treating relapsed refractory multiple myeloma (MM). Due to its oral formulation and favorable safety profile, pomalidomide is generally well tolerated, even among elderly and frail patients. We present a case of severe hypothyroidism induced by pomalidomide in a 71-year-old woman with relapsing/refractory MM. After initiating levothyroxine therapy, her symptoms quickly resolved. We then attempted to resume pomalidomide treatment; the rechallenge proved safe concerning thyroid function. In conclusion, we recommend testing thyroid function in patients prior to and then every 2-3 months during pomalidomide treatment. If drug-induced hypothyroidism occurs, once the patient reaches a state of euthyroidism, a rechallenge can be considered with a good safety profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.